Current perspectives on immunotherapy

Seminars in Oncology

Volumn 41, Issue S5, 2014, Pages S14-S29

  Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGENPANTUCEL L; BMS 936559; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; RILIMOGENE GALVACIREPVEC; RINDOPEPIMUT; SIPULEUCEL T; TECEMOTIDE; TICILIMUMAB; CANCER VACCINE; TUMOR ANTIGEN;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ARTHRALGIA; ASEPTIC MENINGITIS; ASTHENIA; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHOLANGITIS; COLITIS; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIVERTICULITIS; DIZZINESS; DRUG ERUPTION; DRUG FEVER; ENDOPHTHALMITIS; ENTERITIS; FAINTNESS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOPHYSITIS; KIDNEY CARCINOMA; LIMB PAIN; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MELANOMA; MESOTHELIOMA; METASTATIC MELANOMA; MYASTHENIA GRAVIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS DISEASE; PANCREATITIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; RECURRENCE FREE SURVIVAL; REVIEW; SARCOIDOSIS; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; TOXIC HEPATITIS; VACCINATION; VOMITING; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84908277417     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.09.003     Document Type: Article

References (79)

1. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 1995 459 465
2. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
3. J.D. Wolchok, F.S. Hodi, J.S. Weber, J.P. Allison, W.J. Urba, and C. Robert Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma Ann N Y Acad Sci 1291 2013 1 13
4. Yervoy (ipilimumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2013.
5. P. Sharma, K. Wagner, J.D. Wolchok, and J.P. Allison Novel cancer immunotherapy agents with survival benefit: recent successes and next steps Nat Rev Cancer 11 2011 805 812
6. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
7. S.F. Slovin, C.S. Higano, O. Hamid, S. Tejwani, A. Harzstark, and J.J. Alumkal Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
8. M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
9. T.J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
10. J.C. Yang, M. Hughes, U. Kammula, R. Royal, R.M. Sherry, and S.L. Topalian Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
11. F.S. Hodi, S.J. ODay, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
12. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, and C. Garbe Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
13. A.M. Eggermont, V. Chiarion-Sileni, J.J. Grob, R. Dummer, J.D. Wolchok, and H. Schmidt Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 LBA9008
14. B. Sangro, C. Gomez-Martin, M. de la Mata, M. Iñarrairaegui, E. Garralda, and P. Barrera A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C J Hepatol 59 2013 81 88
15. L.H. Camacho, S. Antonia, J. Sosman, J.M. Kirkwood, T.F. Gajewski, and B. Redman Phase I/II trial of tremelimumab in patients with metastatic melanoma J Clin Oncol 27 2009 1075 1081
16. K.Y. Chung, I. Gore, L. Fong, A. Venook, S.B. Beck, and P. Dorazio Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer J Clin Oncol 28 2010 3485 3490
17. J.M. Kirkwood, P. Lorigan, P. Hersey, A. Hauschild, C. Robert, and D. McDermott Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin Cancer Res 16 2010 1042 1048
18. L. Calabro, A. Morra, E. Fonsatti, O. Cutaia, G. Amato, and D. Giannarelli Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial Lancet Oncol 14 2013 1104 1111
19. A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt, J.B. Haanen, and M. Marmol Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
20. P.A. Ott, F.S. Hodi, and C. Robert CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients Clin Cancer Res 19 2013 5300 5309
21. J.S. Weber, K.C. Kähler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
22. K.C. Kaehler, S. Piel, E. Livingstone, B. Schilling, A. Hauschild, and D. Schadendorf Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management Semin Oncol 37 2010 485 498
23. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. G.K. Pennock, W. Waterfield, and J.D. Wolchok Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 35 2012 606 611
25. J.D. Wolchok, A. Hoos, S. ODay, J.S. Weber, O. Hamid, and C. Lebbé Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
26. M. Nishino, A. Giobbie-Hurder, M. Gargano, M. Suda, N.H. Ramaiya, and F.S. Hodi Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Clin Cancer Res 19 2013 3936 3943
27. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D.B. Flies Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
28. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, and H. Nishimura Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
29. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
30. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
31. M.E. Keir, S.C. Liang, I. Guleria, Y.E. Latchman, A. Qipo, and L.A. Albacker Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 203 2006 883 895
32. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
33. H. Nishimura, T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, and A. Matsumori Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 2001 319 322
34. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 2007 813 824
35. A.T. Parsa, J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, and J.J. Barry Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
36. C. Robert, J.C. Soria, and A.M. Eggermont Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies Eur J Cancer 49 2013 2968 2971
37. M. Sznol, H.M. Kluger, F.S. Hodi, D.F. McDermott, R.D. Carvajal, and D.P. Lawrence Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 CRA9006
38. S.L. Topalian, M. Sznol, J.R. Brahmer, D.F. McDermott, D.C. Smith, and S.N. Gettinger Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 3002
39. F.S. Hodi, M. Sznol, H.M. Kluger, D.F. McDermott, R.D. Carvajal, and D.P. Lawrence Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 9002
40. J.S. Weber, R.R. Kudchadkar, G.T. Gibney, B. Yu, P.Y. Cheng, and A. Martinez Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI) [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 3009
41. J.R. Brahmer, L. Horn, S.J. Antonia, D.R. Spigel, L. Gandhi, and L.V. Sequist Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 8030
42. C.G. Drake, D.F. McDermott, M. Sznol, T.K. Choueiri, H.M. Kluger, and J.D. Powderly Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 4514
43. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, and R. Kefford Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
44. A. Ribas, F.S. Hodi, R. Kefford, O. Hamid, A. Daud, and J.D. Wolchok Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 LBA9000
45. O. Hamid, C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, and R. Kefford Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumabrefractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL) [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 3000
46. R. Kefford, A. Ribas, O. Hamid, C. Robert, A. Daud, and J.D. Wolchok Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract] J Clin Oncol (Meeting Abstracts) 32 5s 2014 3005
47. R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, and M. Leiba Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 2008 3044 3051
48. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
49. R.S. Herbst, M.S. Gordon, G.D. Fine, J.A. Sosman, J.-C. Soria, and O. Hamid A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 3000
50. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
51. L. Gelao, C. Criscitiello, A. Esposito, A. Goldhirsch, and G. Curigliano Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander" Toxins (Basel) 6 2014 914 933
52. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280
53. A.M. Menzies, and G.V. Long New combinations and immunotherapies for melanoma: latest evidence and clinical utility Ther Adv Med Oncol 5 2013 278 285
54. C. Kyi, and M.A. Postow Checkpoint blocking antibodies in cancer immunotherapy FEBS Lett 588 2014 368 376
55. C.S. Higano, P.F. Schellhammer, E.J. Small, P.A. Burch, J. Nemunaitis, and L. Yuh Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
56. Provenge (sipuleucel-T) [prescribing information]. Seattle, WA: Dendreon Corporation; 2011.
57. R.B. Sims Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer Vaccine 30 2012 4394 4397
58. E.J. Small, P.F. Schellhammer, C.S. Higano, C.H. Redfern, J.J. Nemunaitis, and F.H. Valone Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094
59. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
60. S.J. Hall, L. Klotz, A.J. Pantuck, D.J. George, J.B. Whitmore, and M.W. Frohlich Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer J Urol 186 2011 877 881
61. S.M. Geary, and A.K. Salem Prostate cancer vaccines: update on clinical development Oncoimmunology 2 2013 e24523
62. D.T. Le, D.M. Pardoll, and E.M. Jaffee Cellular vaccine approaches Cancer J 16 2010 304 310
63. N.D. Shore PROSTVACR targeted immunotherapy candidate for prostate cancer Immunotherapy 6 2014 235 247
64. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, L.M. Glode, D.L. Bilhartz, and M. Wyand Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
65. J.L. Gulley, P.M. Arlen, R.A. Madan, K.Y. Tsang, M.P. Pazdur, and L. Skarupa Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunol Immunother 59 2010 663 674
66. K.S. Gunturu, G.R. Rossi, and M.W. Saif Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 5 2013 81 89
67. J.M. Hardacre, M. Mulcahy, W. Small, M. Talamonti, J. Obel, and S. Krishnamurthi Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study J Gastrointest Surg 17 1 2013 94 100 discussion p. 100-1
68. G.R. Rossi, J.M. Hardacre, M.F. Mulcahy, M.S. Talamonti, J.C. Obel, and C.R. Lima Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 3007
69. B. Agrawal, M.J. Krantz, M.A. Reddish, and B.M. Longenecker Rapid induction of primary human CD4+and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes Int Immunol 10 1998 1907 1916
70. R. Sangha, and C. Butts L-BLP25: a peptide vaccine strategy in non small cell lung cancer Clin Cancer Res 13 2007 s4652 s4654
71. C. Butts, M.A. Socinski, P.L. Mitchell, N. Thatcher, L. Havel, and M. Krzakowski Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 59 68
72. C. Butts, N. Murray, A. Maksymiuk, G. Goss, E. Marshall, and D. Soulières Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 2005 6674 6681
73. J. Vansteenkiste, Zielinski, A. Linder, J. Dahabreh, E.E. Gonzalez, and W. Malinowski Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results J Clin Oncol 31 2013 2396 2403
74. R. Babu, and D.C. Adamson Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma Core Evid 7 2012 93 103
75. C.E. Pelloski, K.V. Ballman, A.F. Furth, L. Zhang, E. Lin, and E.P. Sulman Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2007 2288 2294
76. C.K. Tang, X.Q. Gong, D.K. Moscatello, A.J. Wong, and M.E. Lippman Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer Cancer Res 60 2000 3081 3087
77. R.K. Lai, L.D. Recht, D.A. Reardon, N. Paleologos, M. Groves, and M.R. Rosenfeld Long-term follow-up of ACT III: A Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma [abstract] Neuro Oncol (Meeting Abstracts) 13 Suppl 3 2011 (IM-03)
78. J.H. Sampson, K.D. Aldape, G.E. Archer, A. Coan, A. Desjardins, and A.H. Friedman Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma Neuro Oncol 13 2011 324 333
79. J.H. Sampson, A.B. Heimberger, G.E. Archer, K.D. Aldape, A.H. Friedman, and H.S. Friedman Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 4722 4729